Argentarii LLC Invests $1.29 Million in Zoetis Inc. (NYSE:ZTS)

Argentarii LLC bought a new stake in Zoetis Inc. (NYSE:ZTS) in the fourth quarter, HoldingsChannel.com reports. The institutional investor bought 7,916 shares of the company’s stock, valued at approximately $1,290,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Callahan Advisors LLC lifted its stake in shares of Zoetis by 90.4% in the 4th quarter. Callahan Advisors LLC now owns 13,105 shares of the company’s stock valued at $2,135,000 after acquiring an additional 6,221 shares during the last quarter. Pensionfund Sabic lifted its stake in shares of Zoetis by 55.6% in the 4th quarter. Pensionfund Sabic now owns 11,200 shares of the company’s stock valued at $1,825,000 after acquiring an additional 4,000 shares during the last quarter. CIBC Asset Management Inc lifted its stake in shares of Zoetis by 24.1% in the 4th quarter. CIBC Asset Management Inc now owns 237,369 shares of the company’s stock valued at $38,617,000 after acquiring an additional 46,050 shares during the last quarter. PFW Advisors LLC bought a new stake in shares of Zoetis in the 4th quarter valued at about $1,764,000. Finally, Alberta Investment Management Corp raised its position in Zoetis by 2,050.0% during the 4th quarter. Alberta Investment Management Corp now owns 30,100 shares of the company’s stock valued at $4,904,000 after purchasing an additional 28,700 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Wall Street Analysts Forecast Growth

ZTS has been the subject of a number of recent analyst reports. Piper Sandler upped their price target on Zoetis from $200.00 to $205.00 and gave the company an “overweight” rating in a research report on Thursday, February 27th. UBS Group assumed coverage on Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 price target for the company. Morgan Stanley reduced their target price on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a report on Friday, February 14th. Leerink Partners assumed coverage on Zoetis in a report on Monday, December 2nd. They set an “outperform” rating and a $215.00 target price on the stock. Finally, Barclays upped their target price on Zoetis from $242.00 to $244.00 and gave the stock an “overweight” rating in a report on Friday, February 14th. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average price target of $215.90.

Zoetis Stock Performance

Shares of ZTS opened at $170.34 on Friday. The business’s fifty day simple moving average is $166.72 and its two-hundred day simple moving average is $176.78. The company has a current ratio of 1.75, a quick ratio of 1.08 and a debt-to-equity ratio of 1.09. Zoetis Inc. has a 12 month low of $144.80 and a 12 month high of $200.33. The company has a market cap of $76.28 billion, a price-to-earnings ratio of 31.14, a P/E/G ratio of 2.78 and a beta of 0.94.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, February 13th. The company reported $1.40 EPS for the quarter, beating the consensus estimate of $1.37 by $0.03. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. The business had revenue of $2.32 billion for the quarter, compared to the consensus estimate of $2.30 billion. Research analysts anticipate that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Tuesday, June 3rd. Stockholders of record on Monday, April 21st will be issued a dividend of $0.50 per share. The ex-dividend date is Monday, April 21st. This represents a $2.00 annualized dividend and a dividend yield of 1.17%. Zoetis’s payout ratio is 36.56%.

Insider Activity

In other news, EVP Roxanne Lagano sold 326 shares of the stock in a transaction on Tuesday, February 11th. The stock was sold at an average price of $171.18, for a total transaction of $55,804.68. Following the transaction, the executive vice president now directly owns 16,107 shares of the company’s stock, valued at $2,757,196.26. This represents a 1.98 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.16% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.